Signature Estate & Investment Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Signature Estate & Investment Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Buy	+737	New	+$217K	﹤0.01%	638

Other funds holding ONC

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Barings Charlotte, North Carolina $5.64B AUM 18.33% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Signature Estate & Investment Advisors's ONC Position: Q2 2026 in Review

Signature Estate & Investment Advisors opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 737 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #638 among its holdings.

120 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Signature Estate & Investment Advisors held 737 shares of BeOne Medicines Ltd worth $210K as of Q2 2026.
BeOne Medicines Ltd was a new Signature Estate & Investment Advisors position in Q2 2026.
BeOne Medicines Ltd made up ﹤0.01% of Signature Estate & Investment Advisors's portfolio in Q2 2026, its #638 holding.
120 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Signature Estate & Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.